Approval · Notice of Compliance 2363 · 2001
PREVACID: Notice of Compliance 2363
Issued December 6, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2363
- Date
- December 6, 2001
- Company
- Tap Pharmaceuticals, Inc.Lake Forest, Illinois, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indications: healing of nsaid-associated gastric ulcer and reduction of risk of nsaid-associated gastric ulcer
- Therapeutic class
- K+, h+-atpase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PREVACID | Not yet assigned | — |
Medicinal ingredients
- LANSOPRAZOLE 30 MG per CAP
- LANSOPRAZOLE 15 MG per CAP